Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of intravitreal MK-8748 versus aflibercept in diabetic macular edema
jRCT2030260383Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of tiespectus and aflibercept in diabetic macular edema (DME) (3 arms), sponsored by Merck & Co. Primary endpoint: Mean change in BCVA (ETDRS letters) from baseline to Year 1. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tiespectusaflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on jRCT2030260383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2030260383.